Lundbeck appoints Dr. Rupert Sandbrink as Head of Clinical Development
H. Lundbeck A/S (Lundbeck) Dr. Sandbrink will join Lundbeck on 1 January 2022 as Senior Vice President, Head of Clinical Development. Dr. Sandbrink will play a vital role in advancing Lundbeck’s clinical pipeline towards providing transformative medicines for people living with niche and rare brain diseases. “I am looking forward to Rupert joining our R&D team. He brings strong leadership and broad expertise in all stages of Clinical Development. His impressive track record in successful drug development, in particular his experience in neuroimmunology and rare diseases, matched with